Featured Research Search Results
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06958328
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
Screening Study for Pancreatic Cancer in People with Inherited Mutations
Clinicaltrials.gov identifier:
NCT05058846
Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations
Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact
Surveys, Registries, Interviews
Survey for people diagnosed with lung, liver, pancreatic or thyroid cancer
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer
Clinicaltrials.gov identifier:
NCT06458049
Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes
Pancreatic Cancer Screening Study (CAPS5)
Clinicaltrials.gov identifier:
NCT02000089
Prevention
Screening study for people at high risk for pancreatic cancer
Registry for People at Increased Risk for Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06151223
Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer
Treating Metastatic BRCA1, BRCA2 or PALB2 Pancreatic Cancer Using a New Combination of Chemotherapy Drugs
Clinicaltrials.gov identifier:
NCT06115499
Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Pancreatic Cancer Early Detection for People at High Risk
Clinicaltrials.gov identifier:
NCT04970056
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Observing People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
Clinicaltrials.gov identifier:
NCT01443468
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
Clinicaltrials.gov identifier:
NCT02693535
Treatment
Cancer treatment study for people with advanced solid tumors
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation